Ligand Pharmaceuticals (LGND) Notes Payables (2012 - 2019)

Ligand Pharmaceuticals (LGND) has 6 years of Notes Payables data on file, last reported at $14.3 million in Q2 2019.

• For the quarter ending Q2 2019, Notes Payables fell 96.43% year-over-year to $14.3 million; the trailing twelve-month figure through Jun 2019 stood at $14.3 million (down 96.43% YoY), and the FY2018 full-year result was $23.4 million, changed N/A from the prior year.
• Notes Payables eased to $14.3 million in Q2 2019, from $18.7 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $563.2 million in Q3 2018 to a low of $348000.0 in Q1 2015.
• A 3-year average of $170.2 million and a median of $21.1 million in 2018 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables plunged 93.97% in 2015 and sank 96.43% in 2019, its largest moves.
• Tracing LGND's Notes Payables over 3 years: stood at $348000.0 in 2015, then surged by 6632.76% to $23.4 million in 2018, then plunged by 38.91% to $14.3 million in 2019.
• Business Quant data shows LGND's Notes Payables at $14.3 million in Q2 2019, $18.7 million in Q1 2019, and $23.4 million in Q4 2018.